tiprankstipranks
Trending News
More News >

SynAct Pharma’s Leadership Commits to Long-Term Growth with Lock-Up Agreements

Story Highlights
SynAct Pharma’s Leadership Commits to Long-Term Growth with Lock-Up Agreements

Don’t Miss TipRanks’ Half-Year Sale

SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.

SynAct Pharma AB announced that its board and executive management have entered into lock-up agreements for their shares, which account for 6.9% of the company’s votes and capital, until December 31, 2025. This move underscores the leadership’s commitment to the company’s future development and stability, potentially reassuring stakeholders about the company’s strategic direction and long-term goals.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists aimed at treating autoimmune and inflammatory diseases.

Average Trading Volume: 230,376

Current Market Cap: SEK944.6M

See more data about SYNACT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1